A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel
Abstract The present explorative study was initiated to evaluate the clinical value of 18F-FES PET/CT in monitoring the change of estrogen receptor (ER) expression and potential predictive value in metastatic breast cancer patients. Twenty-two pathology-confirmed breast cancer patients were prospect...
Guardado en:
Autores principales: | Chengcheng Gong, Zhongyi Yang, Yifei Sun, Jian Zhang, Chunlei Zheng, Leiping Wang, Yongping Zhang, Jing Xue, Zhifeng Yao, Herong Pan, Biyun Wang, Yingjian Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5f858afef231473483d6e91ca47f4bd9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
por: Yannan Zhao, et al.
Publicado: (2018) -
How nanotechnology can enhance docetaxel therapy
por: Zhang L, et al.
Publicado: (2013) -
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
por: Jill M. Spoerke, et al.
Publicado: (2016) -
Functionalized docetaxel-loaded lipid-based-nanosuspensions to enhance antitumor efficacy in vivo
por: Pang X, et al.
Publicado: (2019) -
Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy
por: Wang L, et al.
Publicado: (2012)